Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib rollover and long-term treatment continuation study in adults with solid tumors
2025-524905-34-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 2, open-label, single-arm trial of adagrasib in Nonhematologic neoplasms, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
adagrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-524905-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524905-34-00.